Swiss National Bank Has $4.82 Million Position in Enovis Co. (NYSE:ENOV)

Swiss National Bank lifted its position in shares of Enovis Co. (NYSE:ENOV) by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 109,800 shares of the company’s stock after purchasing an additional 2,700 shares during the period. Swiss National Bank owned 0.19% of Enovis worth $4,818,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ENOV. Confluence Investment Management LLC acquired a new position in Enovis during the fourth quarter worth approximately $3,494,000. Geode Capital Management LLC boosted its stake in shares of Enovis by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock worth $39,678,000 after acquiring an additional 80,165 shares during the period. UMB Bank n.a. increased its holdings in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Enovis in the 3rd quarter valued at $1,050,000. Finally, Jane Street Group LLC lifted its holdings in Enovis by 247.6% during the 3rd quarter. Jane Street Group LLC now owns 106,684 shares of the company’s stock valued at $4,593,000 after purchasing an additional 75,988 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC decreased their price objective on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, February 27th.

Enovis Price Performance

Shares of NYSE ENOV opened at $40.01 on Tuesday. The firm has a market cap of $2.28 billion, a P/E ratio of -18.27 and a beta of 2.05. The business’s 50 day moving average is $42.61 and its 200-day moving average is $43.47. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a 1-year low of $35.14 and a 1-year high of $62.79.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Equities research analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.